Wave Life Sciences Ltd Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)-0.54 Intrinsic Value $6.00median of 2 methodsbased on filings through 30 Jun 2026 Market Price $3.70Price as of 30 Sep 2026 Significantly undervaluedIntrinsic value is 62% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (+62%) Data confidence Sign in to view data confidence Market Cap $729.1M Enterprise Value $376.8M Shares Outstanding 207.5M diluted Next Earnings Date9 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Wave Life Sciences is a premier clinical-stage biotechnology company pioneering RNA medicines through its proprietary PRISM platform. The company is uniquely positioned to capture massive value across multiple high-impact therapeutic areas, including obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and Duchenne muscular dystrophy (WVE-N531). Backed by a robust cash runway extending into Q3 2028 and a highly lucrative collaboration with GSK, Wave is transitioning from a platform-validation phase to a commercial-readiness phase with multiple near-term accelerated approval catalysts. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$12.00 Mean target$19.06 High · most bullish analyst$42.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $12.00 The FDA requests additional clinical data or a full confirmatory trial before accepting the NDA for WVE-N531, delaying commercialization. WVE-006's regulatory feedback does not support an accelerated pathway, requiring a long and expensive Phase 3 trial. WVE-007's multidose data shows safety concerns or diminished efficacy compared to single-dose cohorts. Base CaseCentral scenario $19.06 Matches the consensus meanWave successfully files the NDA for WVE-N531 in late 2026 and receives positive regulatory feedback confirming an accelerated approval pathway for WVE-006. WVE-007 initiates its Phase 2a trial on schedule, showing consistent body composition improvements. WVE-008 successfully files its CTA, and the cash runway remains secure beyond 2028. Bull CaseUpside scenario $42.00 The FDA grants accelerated approval for WVE-N531 in DMD and WVE-006 in AATD based on surrogate endpoints (dystrophin expression and Z-AAT reduction). Simultaneously, WVE-007's Phase 2a multidose trial demonstrates best-in-class muscle-sparing fat loss, positioning it as the premier once-to-twice-yearly obesity therapy. GSK advances multiple additional programs, triggering substantial milestone payments. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |